Department / Division:
Radiology / Cardiac and Thoracic Imaging

Address:
DUMC 3808
Durham, NC 27710

Appointment Telephone:
919-684-2711

Office Telephone:
919-684-7311

Fax Telephone:
919-684-7168

• MD, University of Maryland School of Medicine, 1985

• Radiology, Brigham and Women's Hospital (Massachusetts), 1985-1990

• Thoracic Imaging, Brigham and Women's Hospital (Massachusetts), 1989-1990

Clinical Interests:
General thoracic imaging, PET imaging of the thorax, interventional procedures in the thorax, biomarkers

Research Interests:
There are numerous ongoing clinical and basic science investigations in the Thoracic Radiology Section.

Our laboratory work focuses on three fundamental translational areas;

1) Development of molecular imaging probes - We have used several different approaches, including phage display, and in collaboration with our colleagues in the Chemistry Department, a mass spectrometry based method.  These efforts are to develop novel imaging probes that characterize and phenotype tumors.

2) Discovery of novel lung cancer biomarkers – We have used a proteomics approach to discover serum protein biomarkers and developed a protein microarray for the detection of serum autoantibodies. These biomarkers are being evaluated as serum tests for the diagnosis of lung cancer.

3) Early cancer detection and understanding metastasis – In our effort to improve early detection strategies, we have several projects that study the process of metastasis. We are trying to understand the tumor-host interaction, and possible regulatory effects of the immune response in tumors.

Representative Publications:
Gottlin EB, Xiangrong Guan , Pegram C, Cannedy A, Campa MJ, Patz EF Jr. Isolation of novel EGFR-specific VHH domains.  J Biomol Screen.  2009 Jan;14(1):77-85. (2009) Abstract

Birchard KR, Hoang JK, Herndon JE Jr, Patz EF Jr. Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival.  Cancer.  2009 Feb 1;115(3):581-6. (2009) Abstract

Schultz EM, Sanders GD, Trotter PR, Patz EF Jr, Silvestri GA, Owens DK, Gould MK. Validation of two models to estimate the probability of malignancy in patients with solitary pulmonary nodules.  Thorax.  2008 Apr;63(4):335-41. (2008) Abstract

Hopper ED, Roulhac PL, Campa MJ, Patz EF Jr, Fitzgerald MC. Throughput and efficiency of a mass spectrometry-based screening assay for protein-ligand binding detection.  J Am Soc Mass Spectrom.  2008 Sep;19(9):1303-11. (2008) Abstract

Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE 2nd, Patz EF Jr. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.  J Clin Oncol.  2008 Mar 20;26(9):1459-64. (2008) Abstract

Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, Scherpereel A, Mascaux C, Moreau M, Roelandts M, Alard S, Meert AP, Patz EF Jr, Lafitte JJ, Sculier JP,  . Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project.  J Thorac Oncol.  2008 Jan;3(1):6-12. (2008) Abstract

Patz EF Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE 2nd. Panel of serum biomarkers for the diagnosis of lung cancer.  J Clin Oncol.  2007 Dec 10;25(35):5578-83. (2007) Abstract

Hoagland LF 4th, Campa MJ, Gottlin EB, Herndon JE 2nd, Patz EF Jr. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer.  Cancer.  2007 Nov 15;110(10):2260-8. (2007) Abstract

Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH Jr, Patz EF Jr. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.  Cancer.  2006 Dec 15;107(12):2866-72. (2006) Abstract

Patz EF Jr. Lung cancer screening, overdiagnosis bias, and reevaluation of the Mayo Lung Project.  J Natl Cancer Inst.  2006 Jun 7;98(11):724-5. (2006) Abstract

Patz EF Jr. Integration of biomarkers and imaging.  J Thorac Oncol.  2006 Jan;1(1):78-80. (2006) Abstract

MacMahon H, Austin JH, Gamsu G, Herold CJ, Jett JR, Naidich DP, Patz EF Jr, Swensen SJ,  . Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society.  Radiology.  2005 Nov;237(2):395-400. (2005) Abstract

Howard BA, Furumai R, Campa MJ, Rabbani ZN, Vujaskovic Z, Wang XF, Patz EF Jr. Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo.  Cancer Res.  2005 Oct 1;65(19):8853-60. (2005) Abstract

Wang MZ, Shetty JT, Howard BA, Campa MJ, Patz EF Jr, Fitzgerald MC. Thermodynamic analysis of cyclosporin a binding to cyclophilin a in a lung tumor tissue lysate.  Anal Chem.  2004 Aug 1;76(15):4343-8. (2004) Abstract

Suber RL, Flanders VL, Campa MJ, Patz EF Jr. Accentuation of differentially expressed proteins using phage technology.  Anal Biochem.  2004 Oct 15;333(2):351-7. (2004) Abstract

Patz EF Jr, Swensen SJ, Herndon JE 2nd. Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations.  J Clin Oncol.  2004 Jun 1;22(11):2202-6. (2004) Abstract

Howard BA, Zheng Z, Campa MJ, Wang MZ, Sharma A, Haura E, Herndon JE 2nd, Fitzgerald MC, Bepler G, Patz EF Jr. Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer.  Lung Cancer.  2004 Dec;46(3):313-23. (2004) Abstract

Campa MJ, Wang MZ, Howard B, Fitzgerald MC, Patz EF Jr. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer.  Cancer Res.  2003 Apr 1;63(7):1652-6. (2003) Abstract

Marom EM, Sarvis S, Herndon JE 2nd, Patz EF Jr. T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology. 2002 May;223(2):453-9. (2002) Abstract

Marom EM, Erasmus JJ, Pass HI, Patz EF Jr. The role of imaging in malignant pleural mesothelioma. Semin Oncol. 2002 Feb;29(1):26-35. (2002) Abstract

Heyneman LE, Patz EF. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer. 2002 Dec;38(3):261-6. (2002) Abstract

Campa MJ, Serlin SB, Patz EF Jr. Development of novel tumor imaging agents with phage-display combinatorial peptide libraries. Acad Radiol. 2002 Aug;9(8):927-32. (2002) Abstract

Patz EF Jr, Goodman PC. Low-dose spiral computed tomography screening for lung cancer: not ready for prime time. Am J Respir Crit Care Med. 2001 Mar;163(4):813-4. (2001) Abstract

Patz EF Jr, Black WC, Goodman PC. CT screening for lung cancer: not ready for routine practice. Radiology. 2001 Dec;221(3):587-91; discussion 598-9. (2001) Abstract

Marom EM, Aloia TA, Moore MB, Hara M, Herndon JE 2nd, Harpole DH Jr, Goodman PC, Patz EF Jr. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer. 2001 Aug-Sep;33(2-3):99-107. (2001) Abstract

Heyneman LE, Herndon JE, Goodman PC, Patz EF Jr. Stage distribution in patients with a small (less than or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening. Cancer. 2001 Dec 15;92(12):3051-5. (2001) Abstract

Dammas S, Patz EF Jr, Goodman PC. Identification of small lung nodules at autopsy: implications for lung cancer screening and overdiagnosis bias. Lung Cancer. 2001 Jul;33(1):11-6. (2001) Abstract

Crotty E, Patz EF Jr. FDG-PET imaging in patients with paraneoplastic syndromes and suspected small cell lung cancer. J Thorac Imaging. 2001 Apr;16(2):89-93. (2001) Abstract

Aloia T, Bepler G, Harpole D, Goodman PC, McAdams HP, Erasmus JJ, Herndon JE, Patz EF Jr. Integration of peripheral blood biomarkers with computed tomography to differentiate benign from malignant pulmonary opacities. Cancer Detect Prev. 2001;25(4):336-43. (2001) Abstract

Patz EF Jr, Goodman PC, Bepler G. Screening for lung cancer.  N Engl J Med.  2000 Nov 30;343(22):1627-33. (2000) Abstract

Patz EF Jr, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Gilkeson RC, Herndon J. Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Chest. 1998 May;113(5):1305-11. (1998) Abstract

Campa MJ, Schreiber G, Bepler G, Bishop MJ, McNutt RW, Chang KJ, Patz EF Jr. Characterization of delta opioid receptors in lung cancer using a novel nonpeptidic ligand. Cancer Res. 1996 Apr 1;56(7):1695-701. (1996) Abstract